Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Guann-Jen Chern"'
Autor:
Fu Fei Hsu, Chu Chi Lin, Cheng Chin Chiang, Yunching Chen, Yu-Ting Huang, Chih-Chun Chang, Jiantai Timothy Qiu, Hsi Chien Huang, Trinh Kieu Dinh, Guann Jen Chern, Yun Chieh Sung, Kuan Wei Huang, Rui Lin Huang, Yi An Lee, Yung-Chang Lin, Shu-Yi Lin, Donia Alson, Chun-Yen Lin, Yu Chuan Shih, Po Chiao Chang
Publikováno v:
Science Advances
The dual-targeted immunogene therapy that inhibits PD-L1 and provides IL-2 can enhance the therapeutic efficacy of cancer vaccine.
While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tum
While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2bfcaa312e873e1be3ce3e3d3c82829
http://europepmc.org/articles/PMC6962042
http://europepmc.org/articles/PMC6962042
Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma
Autor:
Chia-Lung Tsai, Shao-Feng Huang, Yun-Chieh Sung, Sheng-Kai Wang, Kuan-Wei Huang, Guann-Jen Chern, Rui-Lin Huang, Yu-Tsung Lai, Cheng-Chin Chiang, Ting-Yun Shiue, Yunching Chen, Ting-Lun Ho, Pi-Bei Hwang
Publikováno v:
Biomacromolecules. 19:2330-2339
Successful siRNA therapy requires suitable delivery systems with targeting moieties such as small molecules, peptides, antibodies, or aptamers. Galactose (Gal) residues recognized by the asialoglycoprotein receptor (ASGPR) can serve as potent targeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73ea5424d03a2f7397133165236a1de
https://doi.org/10.1021/acs.biomac.8b00358
https://doi.org/10.1021/acs.biomac.8b00358
Autor:
Yun Chieh Sung, Chun Hung Liu, Sheng-Kai Wang, Chu Chi Lin, Yunching Chen, Jia Yu Liu, Guann Jen Chern, Hsi Chien Huang, Chien-Hsun Wu, Kuan Wei Huang, Han-Chung Wu, Fu Fei Hsu, Jiantai Timothy Qiu
Publikováno v:
Hepatology (Baltimore, Md.). 67(3)
The anti-cancer efficacy of TNF-related apoptosis-inducing ligand (TRAIL)-based therapy is limited due to systemic toxicity, poor bioavailability, and the development of TRAIL-resistance. We developed a tumor-targeted LCPP (Lipid/Calcium/Phosphate/Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbc5b589098649c30717f3cc06fab8c9
https://pubmed.ncbi.nlm.nih.gov/29077214
https://pubmed.ncbi.nlm.nih.gov/29077214
Autor:
Kuan-Wei Huang, Yu-Tsung Lai, Guann-Jen Chern, Shao-Feng Huang, Chia-Lung Tsai, Yun-Chieh Sung, Cheng-Chin Chiang, Pi-Bei Hwang, Ting-Lun Ho, Rui-Lin Huang, Ting-Yun Shiue, Yunching Chen, Sheng-Kai Wang
Publikováno v:
Biomacromolecules; 6/11/2018, Vol. 19 Issue 6, p2330-2339, 10p
Autor:
Kuan-Wei Huang1, Fu-Fei Hsu2, Jiantai Timothy Qiu3,4,5, Guann-Jen Chern1, Yi-An Lee1, Chih-Chun Chang1, Yu-Ting Huang6, Yun-Chieh Sung1, Cheng-Chin Chiang1, Rui-Lin Huang1, Chu-Chi Lin5, Trinh Kieu Dinh1, Hsi-Chien Huang1, Yu-Chuan Shih1, Alson, Donia5, Chun-Yen Lin3,7, Yung-Chang Lin8, Po-Chiao Chang7, Shu-Yi Lin6 shuyi@nhri.org.tw, Yunching Chen1 yunching@mx.nthu.edu.tw
Publikováno v:
Science Advances. 1/30/2020, Vol. 6 Issue 3, p1-13. 13p.